查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1726377

美国小分子创新原料药 CDMO 市场：市场规模、份额、趋势分析（按疾病阶段、服务、客户类型、治疗领域和地区）、细分市场预测（2025-2030 年）

U.S. Small Molecule Innovator API CDMO Market Size, Share & Trends Analysis Report By Stage Type (Preclinical, Clinical, Commercial), By Service, By Customer Type, By Therapeutic Area, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

美国小分子创新者原料药 CDMO 市场成长与趋势：

根据 Grand View Research, Inc. 的新报告，美国小分子创新原料药 CDMO 市场规模预计到 2030 年将达到 126 亿美元，2025 年至 2030 年的复合年增长率为 6.0%。

製药公司外包趋势的日益增长、小分子药物需求的不断增长以及临床试验的激增预计将对美国市场产生积极影响。

小分子继续在全球新疗法的开发中发挥关键作用。特种药物正日益推动美国製药业的成长，尤其是在新兴市场，小分子药物占特种药物销售额的一半以上。此外，提高效率也是製药外包的关键驱动力。随着製药公司面临越来越大的压力来迅速将新药推向市场，外包已成为加速药物开发过程的解决方案。 CDMO 利用其专业知识、经验和最先进的设施来促进高品质药品的快速高效生产，使製药公司能够满足其开发时间表。

製药和生物技术公司越来越多地选择 CDMO 服务来利用他们的专业知识。 CDMO 在製造能力方面具有灵活性和扩充性，使製药公司能够适应不断变化的市场需求并缩短新治疗方法的上市时间。除了提供专业知识和改进的现金流量管理之外，外包还可以带来显着的製造效益，例如降低投资风险。对于早期技术和产品，在产品开发阶段建立昂贵的内部製造能力会带来巨大的风险。同时，外包也是一种规避风险的选择。

在产品的市场需求建立并被理解之前，外包小原料药API 是一种受欢迎的策略。例如，2022 年 5 月，Piramal Pharma Limited 的 Pharma Solutions 业务（一家 CDMO）在其位于安大略省奥罗拉的工厂开设了一个新的 API 设施。这个最先进的设施已经开始运作并完成初步生产。

美国小分子创新者原料药 CDMO 市场：分析概述

  • 按阶段划分，临床部分将在 2024 年占据市场最大收入份额，达到 54.68%。此部分的增长归因于临床试验（I-III 期）活动的增加、小分子开发平臺的不断增长以及专业知识的不断增加。
  • 根据客户类型，预计製药业将在 2024 年占据最大的收入份额，而药物开发资金的增加将推动该行业的成长。
  • 根据治疗领域，肿瘤学领域在 2024 年占据了最大的收益占有率。此外，对先进治疗药物的高研发投入有望最大限度地减轻癌症的疾病负担，从而推动该行业的成长。
  • 2024年美国市场以西方为主，占最大销售份额，达33.07%。预计慢性病患病率上升、对原料药和 CDMO 服务的需求以及医疗保健基础设施的改善等各种因素将极大地推动市场的发展。

目录

第一章 分析方法与范围

第二章执行摘要

第三章 市场驱动因素、趋势与范围

  • 市场联动展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场趋势与展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 投资金筹措视角
  • 临床试验数量分析（2024年）
    • 各阶段临床试验总数（2024 年）
    • 依研究设计分类的临床试验总数（2024 年）
    • 按主要治疗领域分類的临床试验总数（2024 年）
  • 技术状况
    • 小分子创新者将人工智慧融入原料药 CDMO 市场
  • 定价模式分析
  • 法律规范
  • 产业分析工具
    • 波特五力分析
    • PESTEL 与 SWOT 分析
    • COVID-19影响分析

第四章美国小分子创新原料药 CDMO 市场：依疾病阶段的估计与趋势分析

  • 细分仪表板
  • 美国小分子创新原料药 CDMO 市场：依疾病阶段变化分析
  • 美国小分子创新原料药 CDMO 市场：按疾病阶段分類的市场规模和趋势分析（2018-2030 年）
  • 临床前
  • 临床
    • 第一阶段
    • 第二阶段
    • 第三阶段
  • 上市

第五章美国小分子创新原料药 CDMO 市场：依服务估算与趋势分析

  • 细分仪表板
  • 美国小分子创新原料药 CDMO 市场：按服务分類的变化分析
  • 美国小分子创新原料药 CDMO 市场：按服务类型分類的市场规模和趋势分析（2018-2030 年）
  • 製程开发
    • 临床前开发
    • 临床开发
    • 扩大规模优化
  • 契约製造
    • 临床
    • 上市
  • 分析测试和品管
  • 包装和供应链解决方案
  • 其他的

第六章美国小分子创新原料药 CDMO 市场：依顾客类型估算与趋势分析

  • 细分仪表板
  • 美国小分子创新者原料药 CDMO 市场：以客户类型变化分析
  • 美国小分子创新原料药 CDMO 市场：按客户类型分類的市场规模和趋势分析（2018-2030 年）
  • 製药
    • 小型企业
    • 中型公司
    • 大公司
  • 生物技术
    • 小型企业
    • 中型公司
    • 大公司

第七章美国小分子创新原料药 CDMO 市场：依治疗领域的估计与趋势分析

  • 细分仪表板
  • 美国小分子创新原料药 CDMO 市场：依治疗领域分類的产量分析
  • 美国小分子创新原料药 CDMO 市场：按治疗领域分類的市场规模和趋势分析（2018-2030 年）
  • 心血管疾病
  • 肿瘤学
  • 呼吸系统疾病
  • 神经病学
  • 代谢紊乱
  • 感染疾病
  • 其他的

第八章美国小分子创新原料药CDMO 市场：按地区分類的商业分析

  • 区域仪表板
  • 市场规模预测及趋势分析（2018-2030年）
  • 东北
  • 中西部
  • 西
  • 南部

第九章 竞争态势

  • 公司分类
  • 企业市场分析（2024年）
  • 公司简介
    • Lonza Group Ltd.
    • Novo Holdings（Catalent, Inc.）
    • Thermo Fisher Scientific, Inc.
    • Siegfried Holding AG
    • Recipharm AB
    • CordenPharma International
    • Samsung Biologics
    • Labcorp
    • Ajinomoto Bio-Pharma Services
    • Piramal Pharma Solutions
    • Jubilant Life Sciences（Jubilant Biosys Limited）
Product Code: GVR-4-68040-297-9

U.S. Small Molecule Innovator API CDMO Market Growth & Trends:

The U.S. small molecule innovator API CDMO market size is anticipated to reach USD 12.60 billion by 2030 and is projected to grow at a CAGR of 6.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. Agrowing outsourcing trend among pharmaceutical companies, increasing demand for small molecule drugs, and surge in clinical trials are anticipated to influence the U.S. market positively.

Small molecules continue to play an important role in developing new treatments globally. Specialty medicines are increasingly driving U.S. pharmaceutical growth, particularly in developed markets, with small molecule applications accounting for over half of specialty sales. In addition, enhanced efficiency serves as another pivotal driver for pharmaceutical outsourcing. With mounting pressure on pharmaceutical companies to expedite the introduction of new drugs to the market, outsourcing emerges as a solution to accelerate the drug development process. Leveraging their expertise, experience, and cutting-edge equipment, CDMOs facilitate the swift & efficient production of high-quality drugs, enabling pharmaceutical firms to adhere to their development schedules.

The pharmaceutical/biotechnology companies increasingly opt for CDMO services to leverage their expertise. CDMOs offer flexibility & scalability in manufacturing capacity, allowing pharmaceutical companies to adapt to changing market demands and accelerate time to market for new therapies. In addition to providing extended expertise and assisting in improved cash flow management, outsourcing brings significant manufacturing advantages, including reducing investment risks. In the context of early-stage technologies and products, establishing expensive in-house capabilities entails substantial risks across the product development phases. At the same time, outsourcing serves as a risk-averse alternative.

The preference for outsourcing small molecule API has grown as an effective strategy until market demand for products becomes well-established and understood. For instance, in May 2022, Piramal Pharma Limited's Pharma Solutions business, a CDMO, inaugurated a new API facility at its site in Aurora, Ontario. This state-of-the-art plant has commenced operations & has completed its initial production runs.

U.S. Small Molecule Innovator API CDMO Market Report Highlights:

  • Based on stage, the clinical segment led the market with the largest revenue share of 54.68% in 2024. The segment growth can be attributed to the rising clinical trial (Phase I-III) activities, growing small molecule development pipeline, and increasing availability of expertise
  • Based on the customer type, the pharmaceutical segment held the market with the largest revenue share in 2024, attributing to rising funding for drug development is propelling segment growth
  • Based on therapeutic area, the oncology segment accounted for the largest revenue share in 2024. The segment is driven by increasing prevalence of cancer in U.S. In addition, high R&D investments in advanced therapeutics to minimize cancer disease burden are expected to boost segment growth
  • West Group dominated the U.S. market with the largest revenue share of 33.07% in 2024. The presence of various factors, such as increasing prevalence of chronic diseases, demand for APIs & CDMO services and improving healthcare infrastructure is expected to drive market significantly

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Regional Scope
    • 1.1.2. Estimates and Forecast Timeline
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Purchased Database
    • 1.3.3. GVR's Internal Database
    • 1.3.4. Secondary Sources
    • 1.3.5. Primary Research
  • 1.4. Information or Data Analysis
    • 1.4.1. Information Analysis
    • 1.4.2. Market Formulation & Data Visualization
    • 1.4.3. Data Validation & Publishing
  • 1.5. Model Details
    • 1.5.1. Commodity Flow Analysis (Model 1)
    • 1.5.2. Top Down Market Estimation (Model 2)
    • 1.5.3. Value-Chain-Based Sizing & Forecasting (Model 3)
    • 1.5.4. Multivariate Analysis (Model 4)
  • 1.6. List of Secondary Sources
  • 1.7. List of Abbreviations
  • 1.8. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
    • 3.3.2. Market Restraint Analysis
  • 3.4. Investments & Funding Perspective
  • 3.5. Clinical Trials Volume Analysis, (2024)
    • 3.5.1. Total Number of Clinical Trials, by Phase (2024)
    • 3.5.2. Total Number of Clinical Trials, by Study Design (2024)
    • 3.5.3. Total Number of Clinical Trials, by Key Therapeutic Area (2024)
  • 3.6. Technology Landscape
    • 3.6.1. Integration Of AI In Small Molecule Innovator API CDMO Market
  • 3.7. Pricing Model Analysis
  • 3.8. Regulatory Framework
  • 3.9. Industry Analysis Tools
    • 3.9.1. Porter's Five Forces Analysis
    • 3.9.2. PESTEL by SWOT Analysis
    • 3.9.3. COVID-19 Impact Analysis

Chapter 4. U.S. Small Molecule Innovator API CDMO Market: Stage Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Small Molecule Innovator API CDMO Market; Stage Type Movement Analysis
  • 4.3. U.S. Small Molecule Innovator API CDMO Size & Trend Analysis, by Stage Type, 2018 to 2030 (USD Million)
  • 4.4. Preclinical
    • 4.4.1. Preclinical market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Clinical
    • 4.5.1. Clinical market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2. Phase I
      • 4.5.2.1. Phase I market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.3. Phase II
      • 4.5.3.1. Phase II market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.4. Phase III
      • 4.5.4.1. Phase III market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Commercial
    • 4.6.1. Commercial market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Small Molecule Innovator API CDMO Market: Service Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Small Molecule Innovator API CDMO Market; Service Movement Analysis
  • 5.3. U.S. Small Molecule Innovator API CDMO Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
  • 5.4. Process Development
    • 5.4.1. Process development market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Preclinical development
      • 5.4.2.1. Preclinical development market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Clinical development
      • 5.4.3.1. Clinical development market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Scale-up optimization
      • 5.4.4.1. Scale-up optimization market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Contract Manufacturing
    • 5.5.1. Contract manufacturing market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.2. Clinical
      • 5.5.2.1. Clinical market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.3. Commercial
      • 5.5.3.1. Commercial market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Analytical Testing and Quality Control
    • 5.6.1. Analytical testing and quality control market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Packaging and Supply Chain Solutions
    • 5.7.1. Packaging and supply chain solutions market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Small Molecule Innovator API CDMO Market: Customer Type Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Small Molecule Innovator API CDMO Market; Customer Type Movement Analysis
  • 6.3. U.S. Small Molecule Innovator API CDMO Size & Trend Analysis, by Customer Type, 2018 to 2030 (USD Million)
  • 6.4. Pharmaceutical
    • 6.4.1. Pharmaceutical market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Small
      • 6.4.2.1. Small market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Medium
      • 6.4.3.1. Medium market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Large
      • 6.4.4.1. Large market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Biotechnology
    • 6.5.1. Biotechnology market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Small
      • 6.5.2.1. Small market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. Medium
      • 6.5.3.1. Medium market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Large
      • 6.5.4.1. Large market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Small Molecule Innovator API CDMO Market: Therapeutic Area Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. U.S. Small Molecule Innovator API CDMO Market; Therapeutic Area Movement Analysis
  • 7.3. U.S. Small Molecule Innovator API CDMO Size & Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
  • 7.4. Cardiovascular Diseases
    • 7.4.1. Cardiovascular diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Oncology
    • 7.5.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Respiratory Disorders
    • 7.6.1. Respiratory disorders market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Neurology
    • 7.7.1. Neurology market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Metabolic Disorders
    • 7.8.1. Metabolic disorders market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. Infectious Diseases
    • 7.9.1. Infectious diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.10. Others
    • 7.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. U.S. Small Molecule Innovator API CDMO Market: Regional Business Analysis

  • 8.1. Regional Dashboard
  • 8.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030 (USD Million)
  • 8.3. Northeast
    • 8.3.1. Competitive scenario
    • 8.3.2. Northeast small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.3.3. New Jersey
      • 8.3.3.1. Competitive scenario
      • 8.3.3.2. New Jersey small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.3.4. New York
      • 8.3.4.1. Competitive scenario
      • 8.3.4.2. New York small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.3.5. Massachusetts
      • 8.3.5.1. Competitive scenario
      • 8.3.5.2. Massachusetts small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.4. Midwest
    • 8.4.1. Competitive scenario
    • 8.4.2. Midwest small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Illinois
      • 8.4.3.1. Competitive scenario
      • 8.4.3.2. Illinois small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. Missouri
      • 8.4.4.1. Competitive scenario
      • 8.4.4.2. Missouri small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.4.5. North Carolina
      • 8.4.5.1. Competitive scenario
      • 8.4.5.2. North Carolina small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.5. West Group
    • 8.5.1. Competitive scenario
    • 8.5.2. West Group small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. California
      • 8.5.3.1. Competitive scenario
      • 8.5.3.2. California small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.5.4. Washington
      • 8.5.4.1. Competitive scenario
      • 8.5.4.2. Washington small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.6. South
    • 8.6.1. Competitive scenario
    • 8.6.2. South small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. Texas
      • 8.6.3.1. Competitive scenario
      • 8.6.3.2. Texas small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. Florida
      • 8.6.4.1. Competitive scenario
      • 8.6.4.2. Florida small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Georgia
      • 8.6.5.1. Competitive scenario
      • 8.6.5.2. Georgia small Molecule Innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Company Market Position Analysis, 2024
  • 9.3. Company Profiles
    • 9.3.1. Lonza Group Ltd.
      • 9.3.1.1. Company overview
      • 9.3.1.2. Financial performance
      • 9.3.1.3. Service benchmarking
      • 9.3.1.4. Strategic initiatives
    • 9.3.2. Novo Holdings (Catalent, Inc.)
      • 9.3.2.1. Company overview
      • 9.3.2.2. Financial performance
      • 9.3.2.3. Service benchmarking
      • 9.3.2.4. Strategic initiatives
    • 9.3.3. Thermo Fisher Scientific, Inc.
      • 9.3.3.1. Company overview
      • 9.3.3.2. Financial performance
      • 9.3.3.3. Service benchmarking
      • 9.3.3.4. Strategic initiatives
    • 9.3.4. Siegfried Holding AG
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Service benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Recipharm AB
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Service benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. CordenPharma International
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Service benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. Samsung Biologics
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Service benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Labcorp
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Service benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Ajinomoto Bio-Pharma Services
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Service benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Piramal Pharma Solutions
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Service benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Jubilant Life Sciences (Jubilant Biosys Limited)
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Service benchmarking
      • 9.3.11.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 4 U.S. small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 5 U.S. small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 6 U.S. small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 7 U.S. small molecule innovator API CDMO market estimates and forecasts, by region, 2018 - 2030 (USD Million)
  • Table 8 Northeast small molecule innovator API CDMO market estimates and forecasts, by states, 2018 - 2030 (USD Million)
  • Table 9 Northeast small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 10 Northeast small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 11 Northeast small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 12 Northeast small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 13 New Jersey small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 14 New Jersey small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 15 New Jersey small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 16 New Jersey small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 17 New York small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 18 New York small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 19 New York small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 20 New York small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 21 Massachusetts small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 22 Massachusetts small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 23 Massachusetts small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 24 Massachusetts small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 25 Midwest small molecule innovator API CDMO market estimates and forecasts, by states, 2018 - 2030 (USD Million)
  • Table 26 Midwest small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 27 Midwest small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 28 Midwest small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 29 Midwest small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 30 Missouri small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 31 Missouri small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 32 Missouri small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 33 Missouri small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 34 North Carolina small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 35 North Carolina small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 36 North Carolina small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 37 North Carolina small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 38 West Group small molecule innovator API CDMO market estimates and forecasts, by states, 2018 - 2030 (USD Million)
  • Table 39 West Group small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 40 West Group small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 41 West Group small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 42 West Group small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 43 California small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 44 California small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 45 California small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 46 California small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 47 Washington small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 48 Washington small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 49 Washington small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 50 Washington small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 51 South small molecule innovator API CDMO market estimates and forecasts, by states, 2018 - 2030 (USD Million)
  • Table 52 South small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 53 South small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 54 South small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 55 South small molecule innovator API CDMO market estimates and forecasts, by states, 2018 - 2030 (USD Million)
  • Table 56 Texas small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 57 Texas small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 58 Texas small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 59 Texas small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 60 Florida small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 61 Florida small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 62 Florida small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 63 Florida small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)
  • Table 64 Georgia small molecule innovator API CDMO market estimates and forecasts, by stage type, 2018 - 2030 (USD Million)
  • Table 65 Georgia small molecule innovator API CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 66 Georgia small molecule innovator API CDMO market estimates and forecasts, by customer type, 2018 - 2030 (USD Million)
  • Table 67 Georgia small molecule innovator API CDMO market estimates and forecasts, by therapeutic area, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information procurement
  • Fig. 2 Primary research pattern
  • Fig. 3 Market research approaches
  • Fig. 4 Value chain-based sizing & forecasting
  • Fig. 5 Market formulation & validation
  • Fig. 6 small molecule innovator API CDMO market, Segmentation
  • Fig. 7 Market driver analysis
  • Fig. 8 Market restraint relevance analysis
  • Fig. 9 Porter's five forces analysis
  • Fig. 10 PESTEL by SWOT analysis
  • Fig. 11 Regional marketplace: Key takeaways
  • Fig. 12 U.S. preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 13 U.S. clinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 14 U.S. Phase I market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 15 U.S. Phase II market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 16 U.S. Phase III market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 17 U.S. commercial market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 U.S. process development market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 U.S. preclinical development market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 U.S. clinical development market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 U.S. scale-up optimization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 U.S. contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 U.S. clinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 U.S. commercial market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 U.S. analytical testing and quality control market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 U.S. packaging and supply chain solutions market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. pharmaceutical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. small pharmaceutical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 U.S. medium pharmaceutical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 U.S. large pharmaceutical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. biotechnology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. small biotechnology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. medium biotechnology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. large biotechnology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. cardiovascular diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 U.S. oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 U.S. respiratory disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 U.S. neurology market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 U.S. metabolic disorders market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 U.S. infectious diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 U.S. others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Regional Outlook, 2024 & 2030
  • Fig. 44 Northeast small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 New Jersey small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 New York small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Massachusetts small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Midwest small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Illinois small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Missouri small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 North Carolina small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 West Group small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 California small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Washington small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 South small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Texas small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Florida small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Georgia small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)